Pembrolizumab (Keytruda, Merck Sharp and Dohme), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for 'the first-line treatment of locally advanced unresectable or metastatic HER2‑positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS of 1 or more'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price of pembrolizumab is £2,630 per 100 mg per 4 ml vial (excluding VAT; BNF online accessed February 2024).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.